Authors
Latest:
Future Outlook of Advanced Ovarian Cancer TreatmentComprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.
Latest:
The Future of HER2+ Breast Cancer TreatmentPanelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.
Latest:
Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous CarcinomaMarina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma
Latest:
Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast CancerIan Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.
Latest:
Mapping Progress in Pancreatic Cancer Surgery: Leveraging New TechnologyIn this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.
Latest:
Dr Nizam on Enfortumab Vedotin After Maintenance Avelumab in Urothelial CancerAmanda Nizam, MD, discusses findings from the UNITE study of enfortumab vedotin after maintenance avelumab in patients with advanced urothelial carcinoma.
Latest:
Dr Feigin on the Effect of Benzodiazepines on Survival Outcomes in Pancreatic CancerMichael Feigin, PhD, discusses findings from a retrospective study investigating the association between benzodiazepines and survival outcomes in patients with pancreatic cancer.
Latest:
Dr Aredo on the Molecular Distribution of Screening-Eligible Patients With NSCLCJacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.
Latest:
Dr. Lee on the Rationale for Evaluating Telaglenastat in RCCChung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.
Latest:
Mayo Clinic Physicians Seek to Address Bias in Medical EducationThe clinical learning environment for medical trainees is the foundation of medical training programs.
Latest:
Dr Abughanimeh on the Evolution of Targeted Therapy in EGFR+ NSCLCOmar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.
Latest:
Prevalence of Eye Toxicities in Patients With Cancer Is Much Higher Than Previously KnownIn the real-world setting, cases of ocular adverse effects have emerged with greater frequency both in new and established therapies than has been previously observed in many clinical trials.
Latest:
How Genomic Testing and Targeted Therapies Are Shifting the Mindset for Treating Acute Myeloid LeukemiaQuestions and answers with Dr. Eunice Wang, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, an unpaid Astellas consultant
Latest:
Dr. Miller on the Characteristics of Clonal HematopoiesisPeter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.
Latest:
Future Directions in the Treatment of Mantle Cell LymphomaKami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.
Latest:
Dr. Abid on Adaptive Lymphodepletion in CAR T-Cell Recipients in R/R B-Cell NHLMuhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.
Latest:
The Exciting Future of NSCLC TreatmentClosing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.
Latest:
Dr. Serrano on the Rationale for the INVICTUS Trial in Advanced GISTCésar Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.
Latest:
Dr. Klempner on the Results of the DisTinGuish Trial in Advanced Gastroesophageal AdenocarcinomaSam Klempner, MD, discusses the results of the ongoing phase 2a DisTinGuish trial in advanced gastroesophageal adenocarcinoma.
Latest:
Dr Doonan on the Evaluation of IRAK-4 Inhibition With Emavusertib in Metastatic Brain MelanomaBently P. Doonan, MD, discusses the evaluation of targeted inhibition of IRAK-4 with emavusertib in the treatment of metastatic brain melanoma.
Latest:
Closing Thoughts on Intralesional Therapy for Melanoma and CSCCA panel of skin cancer experts offer closing thoughts on intralesional therapy for treating melanoma and CSCC.
Latest:
Dr Son on Urinary and Bowel Anastomotic Leak in Bladder CancerYoung Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.
Latest:
A Challenge to Medical Oncology Training Programs: Promote Equity in TrainingIn her 2020 American Society of Clinical Oncology presidential address, “Equity: Every patient. Every day. Everywhere,” Lori J. Pierce, MD, challenges medical oncology to imagine a future when equity is considered a humanistic standard of oncology practice.
Latest:
Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple MyelomaMichael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.
Latest:
Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AMLSanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.
Latest:
Dr. Hahn on the Investigation of Lenvatinib/Everolimus Vs Cabozantinib in mRCCAndrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.
Latest:
Dr. Sharifi on Methodologies Utilized to Evaluate Link Between Gut Microbiome and Fatal Prostate CancerNima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.
Latest:
Dr. Riedell on the Clinical Utility of EZH2 Mutation Testing in Relapsed/Refractory FLPeter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.
Latest:
Monitoring and Follow-Up of Patients with Chronic GVHDThe panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.
